Clinical trialNCT07094516RecruitingPhase 2Interventional

A Clinical Trial to Learn About the Effects of VHB937 in People With Early Alzheimer's Disease

SponsorNovartis PharmaceuticalsEnrollment407Alzheimer's Disease

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This is a multicentre, randomized, double-blind, placebo-controlled, parallel group Phase II study to evaluate the efficacy and safety of VHB937 in participants with early AD followed by an Extension. The double-blind part is 72 weeks long, followed by an extension.

clinicaltrials.gov ↗

Investigators

No overall officials are registered on this study record. Site-level investigators, where published, appear with their sites below. Why? →

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

74 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Australia

Novartis Investigative Site
Camperdown, New South Wales, Australia
Recruiting
Novartis Investigative Site
Kogarah, New South Wales, Australia
Recruiting
Novartis Investigative Site
Box Hill, Victoria, Australia
Recruiting
Novartis Investigative Site
Heidelberg, Victoria, Australia
Recruiting
Novartis Investigative Site
Nedlands, Western Australia, Australia
Recruiting

Canada

Novartis Investigative Site
London, Ontario, Canada
Recruiting
Novartis Investigative Site
North York, Ontario, Canada
Recruiting
Novartis Investigative Site
Ottawa, Ontario, Canada
Recruiting
Novartis Investigative Site
Toronto, Ontario, Canada
Recruiting
Novartis Investigative Site
Toronto, Ontario, Canada
Recruiting

China

Novartis Investigative Site
Hangzhou, Zhejiang, China
Recruiting
Novartis Investigative Site
Shanghai, China
Recruiting

Czechia

Novartis Investigative Site
Brno, Czechia
Recruiting
Novartis Investigative Site
Prague, Czechia
Recruiting

France

Novartis Investigative Site
Toulouse, Haute Garonne, France
Recruiting
Novartis Investigative Site
Paris, France
Recruiting

Germany

Novartis Investigative Site
Berlin, State of Berlin, Germany
Recruiting
Novartis Investigative Site
Berlin, Germany
Recruiting
Novartis Investigative Site
München, Germany
Recruiting

Italy

Novartis Investigative Site
Cefalù, PA, Italy
Recruiting
Novartis Investigative Site
Perugia, PG, Italy
Recruiting

Japan

Novartis Investigative Site
Ōbu, Aichi-ken, Japan
Recruiting
Novartis Investigative Site
Fujioka, Gunma, Japan
Recruiting
Novartis Investigative Site
Itabashi Ku, Tokyo, Japan
Recruiting
Novartis Investigative Site
Kodaira, Tokyo, Japan
Recruiting
Novartis Investigative Site
Shinjuku Ku, Tokyo, Japan
Recruiting

Netherlands

Novartis Investigative Site
Amsterdam, Netherlands
Recruiting

Poland

Novartis Investigative Site
Bialystok, Poland
Recruiting
Novartis Investigative Site
Oświęcim, Poland
Recruiting
Novartis Investigative Site
Wroclaw, Poland
Recruiting

South Korea

Novartis Investigative Site
Seoul, Korea, South Korea
Recruiting
Novartis Investigative Site
Seoul, Seoul, South Korea
Recruiting
Novartis Investigative Site
Seoul, Seoul, South Korea
Recruiting
Novartis Investigative Site
Incheon, South Korea
Recruiting
Novartis Investigative Site
Incheon, South Korea
Recruiting
Novartis Investigative Site
Seoul, South Korea
Recruiting

Spain

Novartis Investigative Site
Pamplona, Navarre, Spain
Recruiting
Novartis Investigative Site
Valencia, Valencia, Spain
Recruiting
Novartis Investigative Site
Valencia, Spain
Recruiting

Sweden

Novartis Investigative Site
Mölndal, Sweden
Recruiting

34 more sites on the registry record.ClinicalTrials.gov ↗

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

VHB937

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 7 Aug 2025
Primary completion: 14 Sept 2028
Completion: 31 Dec 2030
Last update posted: 26 Jun 2026
Registered enrollment: 407
Registry id: NCT07094516

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.